RK7 Stock Overview
Engages in the formulation and production of food supplements in Italy. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Laboratorio Farmaceutico Erfo S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.20 |
| 52 Week High | €1.28 |
| 52 Week Low | €0.83 |
| Beta | 1.53 |
| 11 Month Change | 0% |
| 3 Month Change | 15.38% |
| 1 Year Change | 30.43% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -28.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| RK7 | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | -0.02% |
| 1Y | 30.4% | -5.9% | 8.2% |
Return vs Industry: RK7 exceeded the German Personal Products industry which returned -5.9% over the past year.
Return vs Market: RK7 exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| RK7 volatility | |
|---|---|
| RK7 Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 3.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RK7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine RK7's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 39 | Alessandro Cute | www.erfo.it |
Laboratorio Farmaceutico Erfo S.p.A. engages in the formulation and production of food supplements in Italy. It produces various types of pharmaceutical forms, such as bottles, single-dose vials and bottles, capsules, tablets, and sachets under the Diètnatural and Gianopharma brands, as well as private label brands. The company offers custom formula creation, regulatory advice, graphics, and packaging services.
Laboratorio Farmaceutico Erfo S.p.A. Fundamentals Summary
| RK7 fundamental statistics | |
|---|---|
| Market cap | €7.94m |
| Earnings (TTM) | €441.11k |
| Revenue (TTM) | €5.82m |
18.0x
P/E Ratio1.4x
P/S RatioIs RK7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RK7 income statement (TTM) | |
|---|---|
| Revenue | €5.82m |
| Cost of Revenue | €3.40m |
| Gross Profit | €2.43m |
| Other Expenses | €1.99m |
| Earnings | €441.11k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.052 |
| Gross Margin | 41.68% |
| Net Profit Margin | 7.58% |
| Debt/Equity Ratio | 5.3% |
How did RK7 perform over the long term?
See historical performance and comparison